Shanghai Kehua Bio-Engineering Co.,Ltd (SHE:002022)

China flag China · Delayed Price · Currency is CNY
6.01
+0.07 (1.18%)
Mar 10, 2026, 2:25 PM CST
0.67%
Market Cap 2.97B
Revenue (ttm) 1.60B
Net Income (ttm) -750.99M
Shares Out 500.65M
EPS (ttm) -1.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,344,240
Average Volume 8,249,423
Open 5.80
Previous Close 5.94
Day's Range 5.80 - 6.03
52-Week Range 4.88 - 8.45
Beta 0.50
RSI 46.54
Earnings Date Apr 17, 2026

About SHE:002022

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of in vitro diagnostic reagents and medical testing equipment and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reag... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1981
Employees 2,033
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002022
Full Company Profile

Financial Performance

In 2024, SHE:002022's revenue was 1.76 billion, a decrease of -27.55% compared to the previous year's 2.43 billion. Losses were -640.60 million, 173.7% more than in 2023.

Financial Statements

News

There is no news available yet.